Two numbers explain almost everything about GLP-1 insurance right now. First: fewer than 1% of denied claims are ever appealed. Second: of the denials that do get appealed, roughly 44% succeed, based on ACA-plan transparency data. Read those together. Insurers say no in bulk, almost nobody pushes back, and pushing back works nearly half the time.
And 2026 has been a year of coverage whiplash. GoodRx research counted 12 million people whose plans dropped Zepbound and 12 million whose plans dropped Wegovy going into 2026. Several state Medicaid programs ended adult obesity coverage in January. Meanwhile, a big door opened in the other direction: Medicare's $50-a-month GLP-1 Bridge started July 1, 2026. If your coverage changed this year, you're not imagining it, and you're not alone.
“I had to do my own investigative work.”
— Deborah Finley, 50, told KFF Health News about winning her appeal
That quote is the whole playbook. Appeals are won on documentation, and the person with the most to gain from assembling it is you.
Why GLP-1 prior auths get denied
- The plan excludes anti-obesity medication entirely. This is a benefit design issue, not a paperwork one. The move here is checking for a second covered indication (see below) or a direct-pay program.
- Missing documentation. BMI history, weight-related conditions, and what you've tried before weren't in the chart when the form was filed. The most fixable denial there is.
- Step therapy. The plan wants something else tried first, or wants proof it already was. If you did try it, that history belongs in the appeal.
- Lifestyle-program requirements. Many plans want 3 to 6 months of documented diet and exercise attempts. Documented is the key word.
The 2026 detail that changes cases: dual indications
Coverage is much likelier when the medication is prescribed for a second FDA-approved indication your plan does cover. Zepbound is approved for obstructive sleep apnea. Wegovy carries a cardiovascular risk indication. If you have sleep apnea, heart disease, or prediabetes in your history, that documentation may matter more to your insurer than your weight history. It has to be in the chart to count, so bring it up at the visit.
The appeal conversation, step by step
- Get the denial reason in plain language. Call the number on the letter and ask.
- Ask the insurer for their specific coverage criteria, in writing.
- Note the deadline. Most commercial plans allow 180 days to appeal, some as little as 60.
- Bring your provider the denial reason plus a one-page history that answers it: dated weight records, conditions, prior attempts and medications.
- Ask directly: “Can we submit a letter of medical necessity, and would a peer-to-peer review help here?”
- If the internal appeal fails, ask about external review. It exists for exactly this.
If coverage is gone: the 2026 self-pay map
Prices moved a lot this year. As of mid-2026: LillyDirect sells Zepbound self-pay from $299 to $449 a month depending on dose. NovoCare sells Wegovy injectable self-pay at $349, and the Wegovy pill from $149 a month at lower strengths. Foundayo, the Lilly pill approved in April 2026, starts around $149 self-pay and can be $25 a month with a commercial-insurance savings card. One caveat worth asking your plan about: direct-pay purchases generally do not count toward your deductible or out-of-pocket maximum.
Medicare: the $50 Bridge
From July 1, 2026 through the end of 2027, Medicare's GLP-1 Bridge offers eligible Part D enrollees a flat $50 monthly copay for Wegovy (pill and injectable), Zepbound KwikPen, and Foundayo. Eligibility requires BMI of 35 or higher, or BMI of 27 or higher plus a qualifying condition such as heart disease or prediabetes. Two fine-print items to discuss with your provider and plan: the $50 does not count toward the Part D deductible or the $2,100 out-of-pocket cap, and the program has its own enrollment mechanics through your Part D plan.
Every one of these paths runs on the same fuel: your documented history, organized so a busy clinician can act on it in the time your visit allows. That's the entire reason the free Appointment Prep Kit exists: a one-page history template plus the questions for a renewal or insurance visit.
Quick answers
How often do GLP-1 insurance appeals succeed?
There is no official GLP-1-specific number, but ACA-plan transparency data shows roughly 44% of appealed denials succeed overall, while fewer than 1% of denials are ever appealed. A first denial is a starting point, not a verdict.
What BMI do you need for insurance to cover Wegovy or Zepbound?
Criteria vary by plan. Many use thresholds like BMI 30+, or 27+ with a weight-related condition, and Medicare's 2026 Bridge uses 35+, or 27+ with a qualifying condition. Ask your insurer for its written criteria rather than guessing.
Does Medicare cover GLP-1s for weight loss in 2026?
Through the Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027), eligible Part D enrollees pay a flat $50 monthly copay for Wegovy, Zepbound KwikPen, and Foundayo. Eligibility is BMI 35+, or 27+ with a qualifying condition.
Does paying cash through LillyDirect or NovoCare count toward my deductible?
Generally no. Direct-pay programs sit outside your insurance, so those payments usually do not accumulate toward your deductible or out-of-pocket maximum. Confirm with your plan.
What should I bring to an appointment about a denied prior authorization?
The denial letter, the insurer's written criteria, and a one-page history that answers the stated denial reason: dated weight records, related conditions, prior programs and medications tried. Then ask your provider about a letter of medical necessity or a peer-to-peer review.